CRDL.US Cardiol Therapeutics Inc Class A

Healthcare Biotechnology USA Stocks
1.0000 USD
Close of Nov 14, 2026
0.8800 2.34
Market cap
USD 122M
P/E
-
P/B
7.46x
ROE
-156.3%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is CRDL.US undervalued?

Graham number

The Graham number of Cardiol Therapeutics Inc Class A cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Cardiol Therapeutics Inc Class A fundamental analysis

No fundamental analysis for Cardiol Therapeutics Inc Class A yet.

Cardiol Therapeutics Inc Class A stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Cardiol Therapeutics Inc Class A

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38,…

Full company profile